Metuchen, NJ, United States of America

Ayesha Sitlani

USPTO Granted Patents = 7 


Average Co-Inventor Count = 8.2

ph-index = 5

Forward Citations = 254(Granted Patents)


Location History:

  • Metuchen, NJ (US) (2012 - 2014)
  • Metuchen, MA (US) (2014 - 2015)

Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Ayesha Sitlani: Pioneering Antagonists for PCSK9

Introduction

Ayesha Sitlani, an innovative inventor based in Metuchen, NJ, has made significant contributions to the field of biomedicine with a focus on PCSK9 antagonists. With a total of seven patents to her name, Sitlani's work offers promising approaches for treating conditions associated with PCSK9 activity.

Latest Patents

Among her noteworthy contributions is the patent for 1B20 PCSK9 antagonists. This invention discloses antagonists that effectively inhibit the function of human proprotein convertase subtilisin-kexin type 9 (PCSK9). The patent encompasses methods for synthesizing these antagonists, as well as nucleic acids encoding them, vectors, and host cells. Another significant patent relates to PCSK9 immunoassays, detailing methods for measuring circulating PCSK9 levels in biological samples using advanced immunoassay techniques, such as solid-phase immunoassays.

Career Highlights

Ayesha Sitlani has garnered extensive experience through her work at the Merck Sharp & Dohme Corporation. Her dedication to research and development has positioned her at the forefront of innovative solutions addressing critical health challenges.

Collaborations

During her career, Sitlani has collaborated with talented colleagues, including Jon H. Condra and Shilpa Pandit. These partnerships have facilitated the advancement of her research and the successful development of her inventions.

Conclusion

Ayesha Sitlani's work exemplifies the vital role of innovation in healthcare. Her extensive research on PCSK9 antagonists not only advances scientific understanding but also holds the potential to transform therapeutic options available for patients. As she continues to develop groundbreaking solutions, Sitlani's contributions will undoubtedly resonate within the biomedical community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…